RxDoctor Payments Data

Michael Jones, MD

Obstetrics & Gynecology · Mexico, MONPI 1972523991

Payments from drug & device makers

$1,782in general payments, 2019–2025

Across 122 payments — averaging $14.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$497
  • Neurocrine Biosciences, Inc.$374
  • Corium, LLC$120
  • AbbVie$98
  • Teva Pharmaceuticals USA, Inc.$98
  • Axsome Therapeutics, Inc.$65
  • plus $530 from 19 others

What the payments were for

  • Food & beverage$1,782100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,782 in reported general payments places this provider in the 70th percentile of 750 obstetrics & gynecology providers in Missouri.

See all obstetrics & gynecology providers in Missouri

Medicare billing

Part B allowed, 2024
$213,176
Medicare patients
263
Services billed
3,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate81$277,736
EliquisApixaban533$155,921
IngrezzaValbenazine Tosylate29$105,233
AustedoDeutetrabenazine15$83,275
AristadaAripiprazole Lauroxil19$64,148
XareltoRivaroxaban184$56,024
JardianceEmpagliflozin164$49,591
Risperdal ConstaRisperidone Microspheres16$41,184
OzempicSemaglutide24$24,392
EntrestoSacubitril/Valsartan85$24,050
FarxigaDapagliflozin Propanediol72$22,893
Paliperidone ErPaliperidone54$20,912
MounjaroTirzepatide18$20,623
LinzessLinaclotide34$19,617
Glucagon Emergency KitGlucagon71$18,886

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$374$105,23329 claims
Teva Pharmaceuticals USA, Inc.Austedo$98$83,27515 claims
Alkermes, Inc.Aristada$58$64,14819 claims
AbbVieLinzess, Vraylar$98$34,45453 claims
Novo NordiskOzempic$16$24,39224 claims
Otsuka America Pharmaceutical, Inc.Rexulti$45$16,54923 claims
Astellas Pharma US IncMyrbetriq$18$10,27747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 750 obstetrics & gynecology providers in Missouri.

Other obstetrics & gynecology in Mexico

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →